The Smart Investor
    Facebook Instagram
    Tuesday, January 31
    Facebook Instagram LinkedIn
    The Smart Investor
    • Home
    • About
      • About Us
      • Careers
    • Smart Investing
      • Getting Started
      • Investing Strategy
      • Smart Analysis
      • Smart Reads
    • Special Free Reports!
    • As Featured on BT
    • Our Services
      • Our Services
      • Subscribe now!
    • Login
    • Cart
    The Smart Investor
    Home»Smart Investing»Can This Medical Stock Benefit from COVID-19?
    Smart Investing

    Can This Medical Stock Benefit from COVID-19?

    Royston YangBy Royston YangMay 21, 2020Updated:July 13, 20204 Mins Read
    Facebook Twitter LinkedIn Email WhatsApp
    Share
    Facebook Twitter LinkedIn Email WhatsApp

    During a pandemic, investors would naturally expect medical and healthcare stocks to benefit.

    However, the situation is not as straightforward as it seems.

    Depending on the specific sub-sector and demographic that the business serves, some healthcare companies may be negatively impacted instead.

    Take IHH Healthcare Berhad (SGX: Q0F) for instance.

    The integrated healthcare provider, which employs more than 55,000 people worldwide and operates over 15,000 licensed beds in 80 hospitals spread out over 10 countries, is facing a mixed outlook.

    While COVID-19 testing and treatment have boosted business for the hospital operator, economic headwinds have dampened demand in other areas.

    Triple whammy

    IHH Healthcare currently faces a triple whammy of challenges stemming from the economic fallout brought about by the pandemic.

    Medical tourism used to be a sweet spot for the group, but this trend has since dwindled significantly due to travel curbs and border closures implemented by countries to control the spread of the coronavirus.

    Over-capacity is a second issue for IHH as many of its hospitals face weak occupancy.

    Finally, the group’s hospitals are experiencing lower volumes as many put off non-urgent treatments due to the lockdowns.

    According to newly-appointed CEO Kelvin Loh, 90% of IHH’s patient volumes and admissions are from residents in their respective home countries.

    The fall in foreign patients for medical tourism is viewed as a short-term headwind and management is confident that it will recover.

    Local patients are deferring non-urgent procedures, thus dampening demand for IHH’s services. Job losses and economic stress may also crimp the locals’ spending ability.

    Huge debt load

    The slowdown is worrying for the group as its balance sheet holds a significant level of debt.

    As of 31 December 2019, IHH held around RM 4.7 billion of cash and gross debt of around RM 9 billion.

    Though revenue for the group increased by 29% year on year to RM 14.9 billion for the fiscal year 2019, net profit (after adjusting for exceptional items) declined by 10% year on year to RM 920.7 million.

    Cost pressures have been building up for the group as it operates in multiple countries, while finance costs (at RM 903.6 million a year) have also eaten up a significant chunk of operating profit.

    Telemedicine and China expansion

    IHH is not standing still, though.

    A global telemedicine initiative was rolled out in early May and is proving to be popular.

    Fortis Healthcare in India, the company’s subsidiary, launched this service back in March and has already done 12,600 teleconsultations across 23 hospitals. The group’s Acibadem hospitals in Turkey have also conducted telemedical consultations since end-March.

    IHH has also invested in telehealth app Doctor Anywhere in Singapore.

    Elsewhere, the group is also proceeding well with its China expansion plans.

    Gleneagles Chengdu Hospital commenced operations in October 2019, while the construction of the new Gleneagles Shanghai Hospital is progressing according to plan.

    The 450-bed multi-speciality general hospital is poised to open during 2020.

    If these two hospitals prove successful, the group may consider opening more hospitals in Beijing, Guangzhou and Tianjin.

    This strategy is akin to Raffles Medical Group Ltd (SGX: BSL). Raffles Medical opened a hospital in early 2019 in Chongqing and is planning to open another in Shanghai in the second half of 2020.

    Get Smart: Mixed signals

    IHH is a sprawling conglomerate of a healthcare provider, making its business tough to track.

    At this point, the group is sending mixed signals on its prospects.

    On one hand, the business is facing tough challenges in the form of dwindling medical tourism and lower patient volumes.

    But on the other hand, it is investing in promising areas such as telemedicine, as well as broadening its reach into China.

    Investors need to monitor the group’s progress closely as the looming economic slowdown, coupled with its heavy debt burden, may stunt the healthcare provider’s growth for many years to come.

    Want to know what stocks we like for our portfolio? See for yourself now. Simply CLICK HERE to scoop up a FREE copy of our special report. As a bonus, we also highlight 6 blue chips stocks trading at a 10-year low. But you will want to hurry – this free report is available for a brief time only. 

    Click here to like and follow us on Facebook and here for our Telegram group.

    Disclaimer: Royston Yang owns shares in Raffles Medical Group Ltd.

    Yahoo
    Share. Facebook Twitter LinkedIn Email WhatsApp

    Related Posts

    Merger and Acquisition

    What Makes Some Serial Acquirers So Successful

    January 30, 2023
    Data Centre (Sunlight)

    5 Key Takeaways from Mapletree Industrial Trust’s Latest Business Update

    January 30, 2023
    Screen Showing Share Prices

    Get Smart: Why You Shouldn’t Focus on Share Prices Alone

    January 29, 2023
    Facebook Instagram LinkedIn Telegram
    • Careers
    • Disclaimer & Privacy Policy
    • Subscription Terms of Service
    © 2023 The Smart Investor. All Rights Reserved. The Smart Investor, thesmartinvestor.com.sg, an investment education website managed by The Investing Hustle Pte Ltd (Company Reg No. 201933459Z) is not licensed or otherwise regulated by the Monetary Authority of Singapore, and in particular, is not licensed or regulated to carry on business in providing any financial advisory service. Accordingly, any information provided on this site is meant purely for informational and investor educational purposes and should not be relied upon as financial advice. No information is presented with the intention to induce any reader to buy, sell, or hold a particular investment product or class of investment products. Rather, the information is presented for the purpose and intentions of educating readers on matters relating to financial literacy and investor education. Accordingly, any statement of opinion on this site is wholly generic and not tailored to take into account the personal needs and unique circumstances of any reader. The Smart Investor does not recommend any particular course of action in relation to any investment product or class of investment products. Readers are encouraged to exercise their own judgment and have regard to their own personal needs and circumstances before making any investment decision, and not rely on any statement of opinion that may be found on this site.

    Type above and press Enter to search. Press Esc to cancel.